Role of high-dose interleukin-2 for melanoma in the age of cellular therapy

Role of high-dose interleukin-2 for melanoma in the age of cellular therapy

Interleukin-2 (IL-2) was one of the first immunotherapies in the treatment of patients with cancer. High-dose bolus IL-2 (HD IL-2) can induce durable complete or partial tumor regression in a small proportion of advanced melanoma and renal cell carcinoma patients. However, its potential for life-thr...

Full description

Saved in:
Bibliographic Details
Main Authors: Mario Sznol, Elizabeth Buchbinder, Rodabe Amaria, Amod Sarnaik, David F McDermott, Michael B Atkins, Ann W Silk, Kim A Margolin, Michael T Lotze, Zeynep Eroglu, Virginia Seery, Allison Betof Warner, Harriet M Kluger, Karam Khaddour
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/5/e011119.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/5/e011119.full

Similar Items